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Abstract
Background: Osteoporosis, osteoporosis-related fractures, and diabetes are considerable health burdens in Japan.
Diabetes in patients with osteoporosis has been reported to be associated with increased fracture risk. This
retrospective analysis of a Japanese hospital claims database investigated the real-world effect of type 2 diabetes
mellitus (T2DM) on the incidence of clinical fractures, costs, and healthcare resource utilization in patients with
osteoporosis and a subgroup of patients prescribed raloxifene.
Methods: Women aged ≥50 years diagnosed with osteoporosis who had a first prescription claim for osteoporosis
treatment with a pre-index period ≥12 months and a post-index period of 30 months were selected from a
database extract (April 2008-July 2013). Patients prescribed raloxifene were classed as a subgroup. Patients
diagnosed with T2DM constituted the T2DM group; all other patients (excluding patients with type 1 diabetes
mellitus) constituted the non-diabetes mellitus (non-DM) group. Groups were matched by exact matching, using
selected baseline characteristics. Patient demographic and clinical characteristics were compared using chi-squared
tests, t-tests, or Wilcoxon rank sum tests. Time to first fracture was examined using Kaplan-Meier survival analysis.
Results: Overall, the T2DM and non-DM groups had 7580 and 7979 patients, respectively; following matching,
there were 3273 patients per group. In the raloxifene subgroup, the T2DM and non-DM groups had 668 and 699
patients, respectively; following matching, there were 239 patients per group. At baseline, the T2DM group (overall
and raloxifene subgroup) had significantly higher healthcare resource utilization and comorbidities. During the
post-index period, a similar pattern was observed in the overall group, even after matching; the T2DM group also
had a higher incidence of fracture. In the raloxifene subgroup, after matching, there were no significant differences
in fracture incidence or costs and fewer differences in healthcare resource utilization between the T2DM and
non-DM groups.
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Conclusions: These findings suggest that comorbid T2DM increases fracture incidence in patients with osteoporosis,
compared with patients without DM. Increases in fracture incidence were accompanied by greater costs and
healthcare resource utilization, which are important considerations for clinical practice in Japan. Further research
investigating the use of raloxifene for treatment of osteoporosis with comorbid T2DM may also be warranted.
Keywords: Aged, Costs, Fracture, Healthcare resource utilization, Hospital claims database analysis, Japan, Osteoporosis,
Raloxifene hydrochloride, Retrospective cohort study, Type 2 diabetes mellitus
Background
Osteoporosis and its resultant fractures are significant
and expanding health burdens, impacting markedly on
patient mortality, morbidity, and quality of life [1]. Given
the prevalence of osteoporosis among the elderly, an
enormous rise in its incidence has been predicted in
Asia, where a 7.6-fold increase in the elderly population
is expected [2]. By 2050, it is projected that 50% of all
hip fractures will occur in Asia [2]. Japan currently has
one of the world’s highest proportions of aged adults
and this proportion is increasing; by 2050, 32% of the
population is expected to be aged over 70 years [3]. The
accompanying rise in the number of patients with osteo-
porosis is likely to have a major impact on healthcare
resource utilization and costs. In Japan, treatment of hip
fractures alone requires an average of 38.2 days in
hospital and treatment costs per year are estimated to be
4.9 billion US dollars [3].
Effective management of osteoporotic fractures requires
careful evaluation not only of osteoporosis but also of the
increasing number of comorbidities that are thought to
influence the risk of fractures [4]. Diabetes is emerging as
one of the most important comorbidities in terms of its
impact on fractures, as suggested by studies in the USA
and in Europe [5, 6]. The presence of diabetes is inde-
pendently associated with an increased risk of fracture,
due in part to alterations in bone structure and strength
[7]; the risk of hip fracture is almost twice as high for pa-
tients with diabetes than for those without diabetes [8].
The prevalence of diabetes, particularly type 2 diabetes
mellitus (T2DM), in Japan is one of the highest in the
world and has been increasing markedly, especially among
the elderly [9, 10]. The rising prevalence of both osteopor-
osis and T2DM in the elderly Japanese population is likely
to lead to greater numbers of patients with osteoporosis
who also have TD2M.
Osteoporosis comorbid with T2DM may require a re-
evaluation of diagnostic criteria or planned treatment;
skeletal fragility due to T2DM can result even without a
noticeable reduction in bone mineral density (BMD),
which has traditionally been used to diagnose osteoporosis
[7, 11]. Although not completely understood, this
increased fragility has been proposed to be due to a deteri-
oration of bone quality rather than bone mass [6, 7], and
osteoporosis treatments that are able to address this
deterioration may be preferred for patients with
T2DM. In a subgroup analysis of the Multiple Out-
comes of Raloxifene Evaluation study, for a small
number of patients, Johnell and coauthors reported
that the osteoporosis drug raloxifene showed higher
efficacy in women with osteoporosis and diabetes
than in women with osteoporosis [12]. A number of
studies have suggested that raloxifene may prevent
the deterioration of bone quality by reducing the for-
mation of detrimental collagen cross-links [13] or by
reducing inhibition of the Wnt/β-catenin signalling
pathway, leading to bone formation and turnover [14,
15]. However, relatively little is known about whether
raloxifene treatment has an impact on the incidence
of fractures in osteoporosis patients with and without
T2DM. There is a need for increased awareness of
the potential impact of T2DM on osteoporotic frac-
tures and how treatment costs, treatment patterns,
and healthcare resource utilization in patients with
osteoporosis may change depending on the presence
or absence of T2DM. This information can help phy-
sicians optimize the treatment and management of
patients with osteoporosis and T2DM.
The aim of this claims database study was to describe
the real-world effect of T2DM comorbidity on the inci-
dence of fracture, costs, and healthcare resource utilization
in patients with osteoporosis in Japan. Furthermore, this
study also aimed to describe the effect of raloxifene treat-
ment on the incidence of fractures in patients with T2DM
compared with patients without diabetes mellitus (DM).
Methods
Data source
This is a retrospective observational study using data
extracted from a medical and pharmacy claims database
provided by the Medical Data Vision Co. Ltd. (MDV;
Tokyo, Japan). The MDV database comprises de-identified,
longitudinal, patient-level medical and pharmacy claims
from 121 hospitals in Japan; these hospitals represent 8%
of all acute care hospitals in Japan. Data from more than
5.57 million unique patients, dating from April 2008 to July
2013, are contained in this extract of the MDV database.
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Study population
Women aged 50 years or older were included in the
study if they had been diagnosed with osteoporosis,
as indicated by International Classification of Diseases
(10th revision) (ICD-10) codes M80 (Osteoporosis
with pathological fracture), M81 (Osteoporosis without
pathological fracture), or M82 (Osteoporosis in diseases
classified elsewhere) and they had a first prescription
claim for osteoporosis medication from March 27, 2009 to
February 12, 2011. The index date was defined as the date
of the first prescription of any osteoporosis medication
(within the MDV database extract corresponding to the
period between April 2008 and July 2013). Other inclusion
criteria were a pre-index period of at least 12 months
(baseline period) and a post-index period of 30 months
(follow-up period), which ensured that the original health-
care provider was accessed continuously for at least
42 months. Patients with type 1 diabetes mellitus (ICD-10
code E10), malnutrition-related diabetes mellitus (ICD-10
code E12), or secondary diabetes (ICD-10 code E13), or
patients receiving antidiabetic medication without a diag-
nosis of T2DM during the study period were excluded
from the study. Patients with osteoporosis were divided
into two groups, depending on whether they had T2DM
or did not have DM. Patients were classified as belonging
to the T2DM group if they had been diagnosed with
T2DM (during either the baseline period or the follow-up
period), as indicated by ICD-10 codes E11 (Type 2
diabetes mellitus) or E14 (Unspecified diabetes mellitus).
All other patients were classified as belonging to the non-
DM group. Patients who initiated raloxifene treatment at
the index date were identified as the raloxifene subgroup.
Outcome measures
The outcome measures examined included the incidence
of any clinical fracture as well as healthcare cost and
resource utilization. Clinical fractures (identified from
ICD-10 codes for fractures; Additional file 1: Table S1)
included both clinical vertebral and non-vertebral
fractures. Pathological fractures due to malignancies or
pathologic bone processes (ICD-10 codes C00-D49) and
traumatic fractures (see Additional file 1: Table S2) were
excluded from the study. Recent fractures were defined
as fractures occurring within the 6 months before the
index date, whereas incident fractures were defined as
new fractures occurring after the index date. The number
of clinical fractures and non-vertebral fractures that
occurred during the baseline period of the study were
reported. In addition to baseline clinical fracture char-
acteristics, the time from index date to first incident
fracture was compared between the two groups during
the 30-month follow-up period.
Healthcare resource utilization, which included
osteoporosis-related tests and any laboratory tests, hospital
admissions, and outpatient visits, as well as the number of
days in hospital, and total costs (medical and pharmaceut-
ical costs combined; Japanese Yen) during the baseline and
follow-up periods were compared between the T2DM and
non-DM groups. The proportion of patients who under-
went tests for BMD, bone formation, and bone resorption
were assessed separately and also as part of osteoporosis-
related tests, which also included imaging tests.
Statistical analysis
The demographics and clinical characteristics of patients
with T2DM and without DM were compared using a chi-
squared test for categorical variables and a t-test for all
continuous variables except for cost. Cost was analyzed
using a Wilcoxon Rank Sum Test. A P value <0.05 was
considered statistically significant. The time to the first
incident fracture was examined using a Kaplan-Meier
survival curve analysis. To reduce the imbalance in covari-
ates between groups, T2DM patients were matched 1:1 to
non-DM patients using an exact matching method. The
comparative analyses of patients with T2DM and without
DM were repeated on the 1:1 matched samples. Groups
were matched using selected baseline characteristics, which
included age, name of osteoporosis drug at index date, gen-
der, comorbidities (dyslipidemia, arteriosclerosis, peripheral
vascular disease, thyroid disease, liver disease, and chronic
kidney disease), other medications (corticosteroid, proton-
pump inhibitor, thyroid hormone, anticonvulsants, and im-
munosuppressants), BMD tests, clinical fractures, recent
fractures, non-vertebral fractures, and hospital admissions.
These baseline characteristics were exactly matched, except
in the case of age, for which a difference of 3 years
(at most) was allowed between groups. Analyses were
performed using SAS Version 9.2 (Cary, NC, USA).
Results
Patient disposition
A total of 233,166 patients in the database were identi-
fied as having a diagnosis of osteoporosis and having
been prescribed medication for osteoporosis from March
27, 2009 to February 12, 2011. Of these patients, 15,559
met the eligibility criteria, with 7580 identified as also
having T2DM; the remaining 7979 patients constituted
the non-DM group. Of the patients who met the eligibil-
ity criteria, a total of 1367 patients (668 with T2DM, 699
without DM) were identified as having been prescribed
raloxifene at the index date, including patients prescribed
a combination of raloxifene and alendronate (28/1367
patients; Table 1).
Age, fracture and clinical characteristics, and healthcare
resource utilization at baseline (overall group)
The average ages of patients in the T2DM and non-DM
groups were 73.4 and 72.9 years, respectively, with those
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Age in years, mean (SD) 73.1 (9.10) 73.4 (8.99) 72.9 (9.19) <0.001 73.7 (9.08) 74.9 (8.45) 72.6 (9.53) <0.001
Age, n (%) <0.001 <0.001
50–54 years 439 (2.8) 203 (2.7) 236 (3.0) 35 (2.6) 8 (1.2) 27 (3.9)
55–59 years 896 (5.8) 413 (5.4) 483 (6.1) 62 (4.5) 22 (3.3) 40 (5.7)
60–64 years 1515 (9.7) 679 (9.0) 836 (10.5) 114 (8.3) 40 (6.0) 74 (10.6)
65–69 years 2309 (14.8) 1064 (14.0) 1245 (15.6) 229 (16.8) 103 (15.4) 126 (18.0)
70–74 years 2967 (19.1) 1504 (19.8) 1463 (18.3) 264 (19.3) 144 (21.6) 120 (17.2)
75–79 years 3406 (21.9) 1695 (22.4) 1711 (21.4) 280 (20.5) 145 (21.7) 135 (19.3)
80 years and older 4027 (25.9) 2022 (26.7) 2005 (25.1) 383 (28.0) 206 (30.8) 177 (25.3)
Fractures, n (%)
Patients with clinical fracturesa 810 (5.2) 405 (5.3) 405 (5.1) 0.453 76 (5.6) 45 (6.7) 31 (4.4) 0.063
Patients with non-vertebral fractures 542 (3.5) 275 (3.6) 267 (3.3) 0.338 62 (4.5) 33 (4.9) 29 (4.1) 0.482
Charlson Comorbidity Index, mean (SD) 2.15 (2.28) 2.76 (2.37) 1.58 (2.03) <0.001 1.70 (1.87) 2.30 (1.99) 1.13 (1.55) <0.001
Comorbidities, n (%)
Dyslipidemia 5329 (34.3) 3671 (48.4) 1658 (20.8) <0.001 429 (31.4) 323 (48.4) 106 (15.2) <0.001
Arteriosclerosis 1487 (9.6) 935 (12.3) 552 (6.9) <0.001 112 (8.2) 75 (11.2) 37 (5.3) <0.001
Peripheral vascular disease 1926 (12.4) 1178 (15.5) 748 (9.4) <0.001 164 (12.0) 96 (14.4) 68 (9.7) 0.008
Thyroid disease 1702 (10.9) 1120 (14.8) 582 (7.3) <0.001 138 (10.1) 93 (13.9) 45 (6.4) <0.001
Liver disease 2817 (18.1) 1914 (25.3) 903 (11.3) <0.001 212 (15.5) 155 (23.2) 57 (8.2) <0.001
Chronic kidney disease 823 (5.3) 647 (8.5) 176 (2.2) <0.001 57 (4.2) 49 (7.3) 8 (1.1) <0.001
Type 2 diabetes 4580 (29.4) 4580 (60.4) - <0.001 357 (26.1) 357 (53.4) - <0.001
Osteoporosis medications initiated, n (%)
Bisphosphonates 8913 (57.3) 4140 (54.6) 4773 (59.8) <0.001 47 (3.4) 18 (2.7) 29 (4.1) 0.140
SERMs 1373 (8.8) 670 (8.8) 703 (8.8) 0.950 1367 (100.0) 668 (100.0) 699 (100.0) -
Active vitamin Db 6155 (39.6) 3101 (40.9) 3054 (38.3) <0.001 385 (28.2) 167 (25.0) 218 (31.2) 0.011
Calcitonin 4 (0.0) 1 (0.0) 3 (0.0) 0.343c - - -
Raloxifene without alendronate 1339 (8.6) 660 (8.7) 679 (8.5) 0.661 1339 (98.0) 660 (98.8) 679 (97.1) 0.030
Raloxifene and alendronate in combination 28 (0.2) 8 (0.1) 20 (0.3) 0.033 28 (2.0) 8 (1.2) 20 (2.9) 0.030
Alendronate without raloxifene 5363 (34.5) 2476 (32.7) 2887 (36.2) <0.001 - - - -
Other medications, n (%)
Corticosteroid 3020 (19.4) 1910 (25.2) 1110 (13.9) <0.001 157 (11.5) 94 (14.1) 63 (9.0) 0.003
Proton-pump inhibitor 3035 (19.5) 2018 (26.6) 1017 (12.7) <0.001 245 (17.9) 168 (25.1) 77 (11.0) <0.001
Thyroid hormone 712 (4.6) 429 (5.7) 283 (3.5) <0.001 41 (3.0) 25 (3.7) 16 (2.3) 0.115
Anticonvulsants 289 (1.9) 181 (2.4) 108 (1.4) <0.001 21 (1.5) 15 (2.2) 6 (0.9) 0.037
Immunosuppressants 953 (6.1) 587 (7.7) 366 (4.6) <0.001 51 (3.7) 29 (4.3) 22 (3.1) 0.244
Diabetes medications, n (%)
Insulin 365 (2.3) 365 (4.8) - <0.001 29 (2.1) 29 (4.3) - <0.001
Metformin 249 (1.6) 249 (3.3) - <0.001 32 (2.3) 32 (4.8) - <0.001
Sulfonylurea 467 (3.0) 467 (6.2) - <0.001 50 (3.7) 50 (7.5) - <0.001
Alpha-glucosidase inhibitor 472 (3.0) 472 (6.2) - <0.001 48 (3.5) 48 (7.2) - <0.001
Thiazolidinedione 219 (1.4) 219 (2.9) - <0.001 25 (1.8) 25 (3.7) - <0.001
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aged 75 years or older constituting the largest proportion
(>46%) of patients in both groups (Table 1); the average
age of patients in the T2DM group was significantly higher
than those in the non-DM group (P < 0.001). There were
no significant differences in the fracture characteristics of
patients in the T2DM and non-DM groups at baseline
(Table 1). In terms of clinical characteristics, compared with
the non-DM group, the T2DM group had a number of sig-
nificant differences (Table 1), including a higher Charlson
Comorbidity Index, a higher percentage of patients with
comorbidities other than T2DM (including dyslipidemia,
arteriosclerosis, peripheral vascular disease, thyroid disease,
liver disease, and chronic kidney disease), a higher per-
centage of patients with active vitamin D (initiation of
prescription), corticosteroid, proton-pump inhibitor, and
diabetic medication prescriptions, and a lower percentage
of patients with bisphosphonate (initiation of prescription)
prescriptions (P < 0.001 for all characteristics).
A greater proportion of patients in the T2DM group
utilized healthcare resources at baseline, when compared
with the non-DM group (Table 1). The T2DM group
had significantly higher total healthcare costs (P < 0.001),
a higher percentage of patients with hospital admissions
(P < 0.001), a higher average number of days spent in
hospital (P < 0.001), and a higher percentage of patients
undergoing laboratory tests (P < 0.001). In contrast, a
significantly smaller percentage of patients in the T2DM
group underwent osteoporosis-related tests (P = 0.010)
or, more specifically, BMD tests (P < 0.001), compared
with the non-DM group.
Following 1:1 exact matching, there were 3273 patients
in both the T2DM and non-DM groups (data not
shown). Comparison of the matched groups showed
fewer significant differences between groups at baseline,
with no differences in fracture characteristics. There
were only a few significant differences in healthcare
resource utilization, including higher total mean (54,931
JPY vs 42,338 JPY; P = 0.011) and median (12,441 JPY vs
9,841 JPY; P < 0.001) costs, as well as a higher percent-
age of patients undergoing laboratory tests (15.0% vs
9.8%; P < 0.001) in the T2DM group.
Age, fracture and clinical characteristics, and healthcare
resource utilization at baseline (raloxifene subgroup)
Within the raloxifene subgroup, the differences in fracture
and clinical characteristics, and in healthcare resource
utilization between the T2DM and non-DM groups
showed a very similar pattern to that of the overall study
group (Table 1). However, there were significant differ-
ences in some clinical characteristics that were observed
in the overall study group but not in the raloxifene
subgroup; there were no significant differences in the
proportion of patients being prescribed bisphosphonates
(initiation of prescription) and immunosuppressants,
between the T2DM-raloxifene and non-DM-raloxifene
subgroups (Table 1). In the raloxifene subgroup, there was
Table 1 Age, fracture and clinical characteristics, and healthcare resource utilization at baseline (Continued)
Resource utilization
BMD test, n (%) 2251 (14.5) 913 (12.0) 1338 (16.8) <0.001 203 (14.9) 71 (10.6) 132 (18.9) <0.001
Bone formation test, n (%) 112 (0.7) 61 (0.8) 51 (0.6) 0.222 8 (0.6) 5 (0.7) 3 (0.4) 0.439c
Bone resorption test, n (%) 484 (3.1) 223 (2.9) 261 (3.3) 0.237 58 (4.2) 25 (3.7) 33 (4.7) 0.370
Osteoporosis-related testsd (baseline), n (%) 3738 (24.0) 1752 (23.1) 1986 (24.9) 0.010 323 (23.6) 133 (19.9) 190 (27.2) 0.002
Osteoporosis-related testsd (baseline), mean
per patient (SD)
0.421 (0.980) 0.434 (1.041) 0.408 (0.918) 0.098 0.358 (0.823) 0.34 (0.859) 0.375 (0.788) 0.433
Laboratory tests, n (%) 1975 (12.7) 1199 (15.8) 776 (9.7) <0.001 179 (13.1) 120 (18.0) 59 (8.4) <0.001
Laboratory tests, mean per patient (SD) 8.983 (41.74) 13.02 (51.36) 5.144 (29.35) <0.001 7.734 (34.43) 11.66 (41.1) 3.986 (26) <0.001
Hospital admissions, n (%) 1410 (9.1) 872 (11.5) 538 (6.7) <0.001 81 (5.9) 54 (8.1) 27 (3.9) <0.001
Hospital admissions, mean per patient (SD) 0.117 (0.47) 0.147 (0.488) 0.088 (0.45) <0.001 0.071 (0.313) 0.099 (0.378) 0.044 (0.232) 0.001
Days in hospital, mean (SD) 3.282 (21.65) 4.33 (27.37) 2.286 (14.15) <0.001 1.688 (9.911) 2.147 (11.16) 1.25 (8.537) 0.097
Outpatient visits, n (%) 15,297 (98.3) 7437 (98.1) 7860 (98.5) 0.056 1353 (99.0) 660 (98.8) 693 (99.1) 0.533
Outpatient visits, mean per patient (SD) 3.567 (8.038) 4.216 (8.932) 2.95 (7.03) <0.001 2.52 (3.836) 2.91 (4.524) 2.147 (2.992) <0.001













Total cost in JPY, median 13,983 18,675 10,783 9,565 13,066 6,654
Abbreviations: BMD bone mineral density, DM diabetes mellitus, JPY Japanese Yen, SD standard deviation, SERM selective estrogen receptor modulator, T2DM type
2 diabetes mellitus
aClinical fractures include vertebral and non-vertebral fractures
bActive vitamin D refers to calcitriol, alfacalcidol or eldecalcitol
cChi-squared test may not be valid as more than 20% of the cells have fewer than 5 expected counts
dOsteoporosis-related tests include bone formation tests, bone resorption tests, imaging tests, and BMD measurements
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a significantly higher percentage of non-DM patients who
initiated active vitamin D (25.0% vs 31.2%; P = 0.011)
prescriptions, in contrast to the overall study group, in
which a higher percentage of T2DM patients initiated
active vitamin D (40.9% vs 38.3%; P < 0.001) prescriptions.
Following 1:1 exact matching, there were 239 patients
in both the T2DM and non-DM groups (data not
shown). Similar to what was observed for the overall
study group, the matched T2DM and non-DM groups
were similar. The only remaining significant difference
between the groups was the higher percentage of patients
who underwent laboratory tests in the T2DM group
(15.9% vs 6.7%; P = 0.001).
Fracture characteristics and health resource utilization
during the follow-up period (overall group)
Before 1:1 exact matching, the T2DM and non-DM
groups showed statistically significant differences in
almost all fracture and health resource utilization charac-
teristics examined during the 30-month follow-up period
(Table 2). The T2DM group had a significantly higher
percentage of patients with clinical (P < 0.001) and non-
vertebral (P < 0.001) fractures compared with the non-DM
group. An analysis of the number of days to the first frac-
ture in both groups showed that patients in the T2DM
group were more likely to develop new fractures than
those in the non-DM group (Table 2). These differ-
ences in fracture characteristics were not observed
during the baseline (pre-matching) period (Table 1).
However, the significant differences in healthcare re-
source utilization observed between the T2DM and
non-DM groups during the follow-up period followed
a similar pattern to what was observed during the
baseline period (Tables 1 and 2).
Following 1:1 exact matching, an almost identical pat-
tern of differences was observed in fracture characteristics
and healthcare resource utilization of the T2DM and non-
DM groups compared with characteristics before match-
ing (Table 2). The only changes were in the number of pa-
tients who underwent osteoporosis-related tests during
the follow-up period and the number of patients with out-
patient visits, which were now significantly higher in the
matched T2DM group than the matched non-DM group
(P = 0.002 and 0.008, respectively). After group matching,
the time to first incident fracture analysis showed that pa-
tients in the T2DM group were more likely to develop
new fractures than those in the non-DM group (Fig. 1).
Fracture characteristics and healthcare resource
utilization during the follow-up period (raloxifene
subgroup)
The significant differences in fracture characteristics and
healthcare resource utilization observed between the
T2DM and non-DM groups in the raloxifene subgroup
during the follow-up period (Table 3) followed a similar
pattern to that observed during the baseline (pre-match-
ing) period (Table 1). However, in contrast to the baseline
period, the T2DM group had a significantly higher num-
ber of days spent in hospital (P < 0.001), compared with
the non-DM group (Table 3). Unlike the overall study
group (Table 2), there were no statistically significant dif-
ferences in the fracture characteristics of the T2DM-
raloxifene group compared with the non-DM-raloxifene
group (Table 3). However, in terms of healthcare resource
utilization, the pattern of differences observed between
the T2DM-raloxifene and non-DM-raloxifene groups
(pre-matching) was similar to what was observed for the
overall study group (pre- and post-matching).
Following 1:1 exact matching, the number of signifi-
cant differences between the T2DM and non-DM groups
in the raloxifene subgroup was substantially reduced
(Table 3). After matching, there were no differences in
fracture characteristics or in the likelihood of fractures
between groups (Table 3 and Fig. 2), consistent with
what was observed before matching. The significant dif-
ferences remaining after matching were in the percent-
ages of patients with hospital admissions and laboratory
tests (all of which were higher in the T2DM group), and
the significantly lower percentage of patients in the
T2DM group who underwent BMD tests.
Compared with the overall study group (post-matching;
Table 2), after matching, the T2DM and non-DM groups
in the raloxifene subgroup were more similar to each
other (Table 3). In contrast to the overall study group,
there were no significant differences in any of the fracture
characteristics and there were no significant differences in
the percentages of patients who underwent bone resorp-
tion tests or osteoporosis-related tests, the average num-
ber of outpatient visits per patient, or in the number of
days spent in hospital.
Discussion
To our knowledge, this is the first study to examine the
real-world impact of T2DM on the incidence of fracture,
cost, and healthcare resource utilization in patients with
osteoporosis in Japan. As might be expected, at baseline,
patients with T2DM incurred greater costs, utilized pro-
portionally greater healthcare resources, and were in
poorer health than patients without DM (Table 1). This
is consistent with studies highlighting the considerable
financial cost and resources required to adequately man-
age patients with T2DM, independent of osteoporosis
[16, 17]. A similar pattern of differences in fracture
characteristics and healthcare resource utilization was
observed between the two groups following initiation of
osteoporosis medication (during the follow-up period),
even after 1:1 exact matching of baseline characteristics
(Table 2). Although a proportion of patients in both the
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Patients with clinical fracturesa, n (%) 1882 (12.1) 1029 (13.6) 853 (10.7) <0.001 738 (11.3) 415 (12.7) 323 (9.9) <0.001
Number of days to first fracture, mean (SD) 442.8 (259.0) 443.4 (257.7) 442.2 (260.6) <0.0001b 454.5 (261.8) 455.5 (259.2) 453.3 (265.5) 0.0003b
Patients with non-vertebral fractures, n (%) 1454 (9.3) 817 (10.8) 637 (8.0) <0.001 565 (8.6) 329 (10.1) 236 (7.2) <0.001
Resource utilization
BMD test, n (%) 6633 (42.6) 2739 (36.1) 3894 (48.8) <0.001 2726 (41.6) 1271 (38.8) 1455 (44.5) <0.001
Bone formation test, n (%) 768 (4.9) 384 (5.1) 384 (4.8) 0.466 279 (4.3) 135 (4.1) 144 (4.4) 0.582
Bone resorption test, n (%) 1535 (9.9) 634 (8.4) 901 (11.3) <0.001 609 (9.3) 278 (8.5) 331 (10.1) 0.024
Osteoporosis-related testsc (post-baseline), n (%) 11,454 (73.6) 5594 (73.8) 5860 (73.4) 0.614 4748 (72.5) 2430 (74.2) 2318 (70.8) 0.002
Osteoporosis-related testsc (post-baseline),
mean per patient (SD)
2.873 (3.198) 2.994 (3.369) 2.758 (3.022) <0.001 2.719 (3.057) 2.86 (3.118) 2.578 (2.989) <0.001
Hospital admissions, n (%) 4799 (30.8) 2980 (39.3) 1819 (22.8) <0.001 1941 (29.7) 1177 (36.0) 764 (23.3) <0.001
Hospital admissions, mean per patient (SD) 0.585 (1.451) 0.776 (1.646) 0.405 (1.212) <0.001 0.515 (1.46) 0.635 (1.687) 0.395 (1.179) <0.001
Days in hospital, mean (SD) 11.58 (36.23) 16.02 (44.22) 7.366 (25.8) <0.001 9.622 (30.03) 12.33 (34.71) 6.914 (24.16) <0.001
Outpatient visits, n (%) 15,511 (99.7) 7561 (99.7) 7950 (99.6) 0.205 6529 (99.7) 3270 (99.9) 3259 (99.6) 0.008
Outpatient visits, mean per patient (SD) 39.52 (54.6) 46.84 (58.98) 32.56 (49.09) <0.001 36.26 (45.97) 40.06 (45.13) 32.45 (46.5) <0.001
Laboratory tests, n (%) 3010 (19.3) 1645 (21.7) 1365 (17.1) <0.001 1338 (20.4) 762 (23.3) 576 (17.6) <0.001
Laboratory tests, mean per patient (SD) 52.11 (182.8) 68.84 (215.1) 36.21 (144) <0.001 47.56 (157.9) 57.57 (167.1) 37.54 (147.5) <0.001
Total cost in JPY, mean (SD) 1,130,000 (2,390,000) 1,490,000 (2,750,000) 782,000 (1,940,000) <0.001 912,000 (1,860,000) 1,080,000 (1,930,000) 743,000 (1,770,000) <0.001
Total cost in JPY, median 322,000 517,000 209,000 295,000 401,000 219,000 <0.001d
Abbreviations: BMD bone mineral density, DM diabetes mellitus, JPY Japanese Yen, SD standard deviation, T2DM type 2 diabetes mellitus
aClinical fractures include vertebral and non-vertebral fractures
bP value from Log Rank test
cOsteoporosis-related tests include bone formation tests, bone resorption tests, imaging tests, and BMD measurements













T2DM and non-DM groups developed clinical fractures
during the follow-up period, the proportion in the
T2DM group was significantly larger than in the non-
DM group (12.7% vs 9.9%; P < 0.001; Table 2). This
difference reflects the additional fracture risk posed by
T2DM (independent of osteoporosis), as has been
observed in previous studies [4, 5, 8]. These findings
suggest that both physicians and patients need to care-
fully consider the potential impact of T2DM on the
treatment and management of osteoporosis in order to
achieve the best clinical outcome and to ensure the most
efficient use of healthcare resources.
We used 1:1 exact matching to adjust for differences
between the T2DM and non-DM groups, which resulted
in the removal of most of the significant baseline differ-
ences between the two groups, indicating reduction of
some of the existing bias. However, during the follow-up
period, matching did little to change the pattern of
significant differences observed between the two groups,
indicating that these differences were likely to be real.
Of note was the fact that the proportion of patients in
the T2DM group who underwent BMD tests was signifi-
cantly smaller than that in the non-DM group; this
pattern was observed during follow-up (38.8% vs 44.5%;
P < 0.001). This difference may be partly explained by
the fact that BMD measurements have been suggested
to be of limited use in predicting fracture risk in patients
with chronic kidney disease (CKD), particularly in the
later stages of CKD [18]. In fact, the 2009 Kidney
Disease Improving Global Outcomes CKD-Mineral and
Bone Disorder (CKD-MBD) Work Group does not
recommend routine BMD testing to estimate fracture
risk in patients with stage 3-5D CKD with evidence of
CKD-MBD [19]. As the T2DM group had more patients
with CKD, a lower rate of BMD testing amongst patients
with CKD may have contributed to the significantly
smaller proportion of patients undergoing BMD tests in
the T2DM group compared with the non-DM group.
Another explanation for the difference in BMD tests be-
tween the two groups may be that given the seriousness
of the comorbidities and complications associated with
diabetes (eg, nephropathy and retinopathy), patients di-
agnosed with T2DM may have prioritized management
of T2DM in favor of osteoporosis [7], leading to fewer
BMD tests being carried out. In Japan, patients with
diabetes are often treated by endocrinologists, diabetol-
ogists, or internists, whereas patients with osteoporosis
are often treated by orthopedic surgeons. This difference
in medical care can lead to different treatment priorities,
which may mean that patients with osteoporosis comor-
bid with diabetes may not receive optimal treatment for
the increased fracture risk. The findings of this study
highlight the need to educate both patients and physi-
cians about the impact of diabetes on fracture risk so
that screening and treatment of osteoporosis can be
modified appropriately.
Compared with the overall study group, similar patterns
in fracture characteristics and healthcare resource
utilization were observed in the raloxifene subgroup,
before matching (Table 3). However, in contrast to the
overall study group, there were no statistically significant
differences in any of the fracture characteristics between
the T2DM and non-DM groups in the raloxifene
subgroup during the 30 months of the follow-up period;
this was observed in both unadjusted (clinical fracture:
14.4% vs 13.3%; P = 0.568) and matched groups (clinical
Fig. 1 Kaplan-Meier curve of time to first incident fracture for the overall study group, post-matching. Abbreviations: DM = diabetes mellitus;
T2DM = type 2 diabetes mellitus
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Patients with clinical fracturesa, n (%) 189 (13.8) 96 (14.4) 93 (13.3) 0.568 61 (12.8) 29 (12.1) 32 (13.4) 0.681
Number of days to first fracture, mean (SD) 440.8 (258.9) 398.2 (250.9) 484.8 (261) 0.499b 423.7 (248.7) 381.9 (244) 461.6 (250.6) 0.717b
Patients with non-vertebral fractures, n (%) 148 (10.8) 79 (11.8) 69 (9.9) 0.245 51 (10.7) 24 (10.0) 27 (11.3) 0.657
Resource utilization
BMD test, n (%) 634 (46.4) 239 (35.8) 395 (56.5) <0.001 232 (48.5) 96 (40.2) 136 (56.9) <0.001
Bone formation test, n (%) 86 (6.3) 35 (5.2) 51 (7.3) 0.117 29 (6.1) 14 (5.9) 15 (6.3) 0.848
Bone resorption test, n (%) 157 (11.5) 60 (9.0) 97 (13.9) 0.005 54 (11.3) 26 (10.9) 28 (11.7) 0.773
Osteoporosis-related testsc (post-baseline), n (%) 1029 (75.3) 488 (73.1) 541 (77.4) 0.063 364 (76.2) 178 (74.5) 186 (77.8) 0.391
Osteoporosis-related testsc (post-baseline), mean per
patient (SD)
2.863 (3.031) 2.867 (3.157) 2.86 (2.909) 0.966 2.747 (2.698) 2.816 (2.745) 2.678 (2.654) 0.576
Hospital admissions, n (%) 383 (28.0) 243 (36.4) 140 (20.0) <0.001 129 (27.0) 79 (33.1) 50 (20.9) 0.003
Hospital admissions, mean per patient (SD) 0.49 (1.053) 0.668 (1.246) 0.32 (0.791) <0.001 0.416 (0.849) 0.49 (0.839) 0.343 (0.855) 0.059
Days in hospital, mean (SD) 9.306 (29.13) 12.69 (35.26) 6.076 (21.23) <0.001 8.073 (30.44) 9.586 (34.95) 6.561 (25.13) 0.278
Outpatient visits, n (%) 1367 (100.0) 668 (100.0) 699 (100.0) - 478 (100.0) 239 (100.0) 239 (100.0) -
Outpatient visits, mean per patient (SD) 32.72 (38.37) 38.61 (39.44) 27.09 (36.47) <0.001 30.59 (34.09) 31.84 (23.96) 29.34 (41.85) 0.424
Laboratory tests, n (%) 268 (19.6) 162 (24.3) 106 (15.2) <0.001 88 (18.4) 55 (23.0) 33 (13.8) 0.009
Laboratory tests, mean per patient (SD) 37.93 (127.3) 50.91 (151.9) 25.53 (96.77) <0.001 27.54 (79.15) 36.03 (91.74) 19.05 (63.21) 0.019
Total cost in JPY, mean (SD) 750,000 (1,560,000) 1,010,000 (1,800,000) 500,000 (1,230,000) <0.001 589,000 (1,170,000) 665,000 (980,000) 513,000 (1,340,000) 0.158
Total cost in JPY, median 240,000 396,000 144,000 215,000 314,000 150,000 <0.001d
Abbreviations: BMD bone mineral density, DM diabetes mellitus, JPY Japanese Yen, SD standard deviation, T2DM type 2 diabetes mellitus
aClinical fractures include vertebral and non-vertebral fractures
bP value from Log Rank test
cOsteoporosis-related tests include bone formation tests, bone resorption tests, imaging tests, and bone mineral density measurements













fracture: 12.1% vs 13.4% P = 0.681). Following matching,
there were even fewer significant differences between the
two groups in terms of healthcare resource utilization.
Taken together, these results may indicate that comorbid
diabetes had a lower impact on fractures and healthcare
resource utilization in patients who were prescribed ralox-
ifene. Based on its mechanism of action, raloxifene has
been proposed to affect diabetes-related fracture risk in a
number of ways. Raloxifene may decrease the accumula-
tion of advanced glycation endproducts, which are
thought to reduce bone quality [11, 20]. Raloxifene has
also been suggested to improve bone quality by increasing
the formation of enzymatic cross-links in bone [13] and
by improving collagen spacing [21] and bone toughness
[22]. It is important to note that we cannot confirm that
raloxifene alone is responsible for the beneficial effects ob-
served or that these effects may not be mediated by other
osteoporosis treatments. Furthermore, a recent study has
suggested that the efficacy of bisphosophonates and
raloxifene in reducing fracture risk is not affected by the
presence of diabetes [23]. Nevertheless, our results indi-
cate that further testing of raloxifene in this clinical set-
ting, particularly in comparison with other osteoporosis
medications, may be warranted.
In addition to considerations surrounding the efficacy
of different osteoporosis treatments in patients with
T2DM, physicians may also have to consider the safety
profile of certain osteoporosis treatments in the context
of diabetes. For instance, a retrospective analysis by
Khamaisi and coauthors suggested that patients with
diabetes may be at increased risk of developing osteo-
necrosis of the jaw when treated with bisphosphonates
[24]. Conversely, physicians should also consider the
effects of treatments for T2DM on osteoporosis. A meta-
analysis of 10 randomized controlled trials suggested that
long-term thiazolidinedione use doubles the risk of
fractures among women with T2DM [25]. It is clear that
comorbidity with T2DM adds further complexity to clin-
ical decision-making during the treatment of osteoporosis.
The strengths of this study include the large number
of patients and the fact that the analyses were performed
on an extensive medical claims database, which reflects
real-world clinical practice in more than 100 hospitals in
Japan. Given that the data are drawn from a claims
database, there are several inherent limitations, which
include a reliance on ICD-10 codes being applied accur-
ately and the fact that outcomes cannot be directly
measured but must be inferred from available data. Al-
though an exact matching method was used to minimize
the differences between the T2DM and non-DM groups,
there may have been additional unobserved confounding
factors that were not considered during the matching
process, which may have introduced bias into the com-
parisons. Additional limitations include the relatively
short follow-up period, which may underestimate the in-
cidence of fractures. Patients who were diagnosed with
T2DM during the baseline period were not distinguished
from those who were diagnosed during the follow-up
period. The severity of osteoporosis in each patient was
also not known; disproportionate numbers of patients
with severe osteoporosis in each group may have intro-
duced bias into the study. Patients may have also received
their prescriptions from sources other than hospitals,
which would not have been captured by the database
utilized. Varying levels of adherence to and persistence
with osteoporosis medications may have also affected the
Fig. 2 Kaplan-Meier curve of time to first incident fracture for the raloxifene subgroup, post-matching. Abbreviation: DM = diabetes mellitus;
T2DM = type 2 diabetes mellitus
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incidence of fractures observed. These limitations should
be considered when interpreting the findings of this study
and it should also be noted that no causative effects can
be identified from this analysis.
Conclusion
This study is one of the first to highlight the impact of
T2DM on osteoporosis in real-world clinical practice in
Japan. Patients with osteoporosis and T2DM had a
higher incidence of fractures, utilized proportionally
greater healthcare resources, and incurred proportionally
higher healthcare costs, than matched patients without
DM. This has important implications for clinical practice,
as greater education of both patients and physicians may
increase awareness of the substantial impact of diabetes
on fracture risk in osteoporosis. In particular, physicians
have to consider not only the increased fracture risk but
the appropriateness of treatments for both osteoporosis
and T2DM. Our analysis of study patients treated with
raloxifene indicates that further assessment of this treat-
ment in the context of T2DM may be warranted. Given
the sizeable impact of osteoporosis on the economy and
healthcare system of the “super-aging” society in Japan
[26], strategies to offset the additional burden of T2DM
on osteoporotic fractures may be of substantial value.
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